Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for process/pmg6 returned no results
Showing 541 to 555 of 2854 results for process

  1. Semaglutide for managing overweight and obesity in children 6 to 11 years [TSID12381]

    Awaiting development Reference number: GID-TA12020 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Povorcitinib for treating prurigo nodularis [TSID12385]

    Awaiting development Reference number: GID-TA12018 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Pelabresib with ruxolitinib for treating myelofibrosis [TSID12391]

    Awaiting development Reference number: GID-TA12017 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Nipocalimab for treating generalised myasthenia gravis in people 2 to 17 yearslimab for Myasthenia gravis [TSID12382]

    Awaiting development Reference number: GID-TA12015 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Lemborexan for treating insomnia [TSID12397]

    Awaiting development Reference number: GID-TA12011 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Depemokimab for treating eosinophilic granulomatosis with polyangiitis [TSID12383]

    Awaiting development Reference number: GID-TA12007 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Crovalimab for treating atypical haemolytic uraemic syndrome [TSID12386]

    Awaiting development Reference number: GID-TA12006 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Amlitelimab for treating moderate to severe atopic dermatitis in people 12 years and over [TSID12394]

    Awaiting development Reference number: GID-TA12005 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Olomorasib with pembrolizumab for untreated KRAS G12C mutation- and PD-L1-positive unresectable advanced non-small-cell lung cancer [TSID12375]

    Awaiting development Reference number: GID-TA12003 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Olomorasib in combination for untreated KRAS G12C mutation-positive unresectable advanced non-squamous non-small-cell lung cancer [TSID12376]

    Awaiting development Reference number: GID-TA12001 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Etavopivat for treating sickle cell disease in people 12 years and over [ID6698]

    Awaiting development Reference number: GID-TA11912 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Dulaglutide for treating type 2 diabetes [ID1451]

    Awaiting development Reference number: GID-TA10439 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6708]

    Awaiting development Reference number: GID-TA11953 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Suspected sepsis in under 16s: recognition, diagnosis and early management

    In development Reference number: GID-NG10466 Expected publication date:  17 February 2027

    NICE guideline
    In development

  15. Asundexian for preventing stroke after acute non-cardioembolic ischaemic stroke or high-risk transient ischaemic attack [TSID12406]

    Awaiting development Reference number: GID-TA12033 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development